Anecortave acetate

From WikiMD's WELLNESSPEDIA

Anecortave Acetate[edit]

Anecortave acetate is a synthetic corticosteroid derivative that has been investigated for its potential use in the treatment of ocular conditions, particularly those involving neovascularization. It is a derivative of cortisol and is chemically related to other corticosteroids, but it has been modified to reduce its glucocorticoid activity while retaining its anti-angiogenic properties.

Mechanism of Action[edit]

Anecortave acetate functions primarily as an anti-angiogenic agent. It inhibits the formation of new blood vessels, a process known as angiogenesis, which is a critical factor in the progression of several ocular diseases. The drug achieves this by interfering with the signaling pathways that promote the proliferation and migration of endothelial cells, which are essential for new blood vessel formation.

Clinical Applications[edit]

Anecortave acetate has been studied for its potential use in treating age-related macular degeneration (AMD), a leading cause of vision loss in the elderly. In AMD, abnormal blood vessels grow under the retina, leading to vision impairment. By inhibiting angiogenesis, anecortave acetate aims to prevent the progression of this condition.

Administration[edit]

The drug is typically administered as a periocular injection, which involves delivering the medication to the area surrounding the eye. This method allows for localized treatment, minimizing systemic exposure and potential side effects associated with corticosteroids.

Research and Development[edit]

While anecortave acetate showed promise in early clinical trials, subsequent studies yielded mixed results regarding its efficacy compared to other treatments, such as anti-VEGF therapies. As a result, its development has been limited, and it is not widely used in clinical practice.

Related Pages[edit]



Stub icon

This ophthalmology article is a stub. You can help WikiMD by expanding the page.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Anecortave_acetate&oldid=6623110"